Molecular Imaging in Drug Discovery and Development
This whitepaper discusses the role of molecular imaging in the drug discovery and development process.
Key takeaways
Preclinical imaging can support different phases of drug discovery and development, hereby reducing biological variability and cost.
Preclinical imaging is a non-invasive and longitudinal research tool, it is fully compliant with the 3Rs principles which allows the researchers to study interactions of new compounds in real time in a quantitative manner at a molecular level. Additionally, it provides the ability to repeatedly and non-invasively monitor treatment response. Importantly, preclinical imaging can also increase your research throughput significantly.
There are many well-established techniques in drug discovery and development that can be complemented with preclinical molecular imaging, providing similar or additional info in a non-invasive and quantitative manner (e.g. target expression levels, biodistribution, etc.)
CUBES offers the drug discovery community a benchtop imaging platform to produce reproducible, quantitative and biologically relevant data that enables an acceleration in the drug discovery process
Download this Document:
Please enter your details below to gain on-demand access to this Document.